Skip to main content

Table 1 Patient’s characteristics

From: The effect of intra-nasal tetra sodium pyrophosphate on decreasing elevated nasal calcium and improving olfactory function post COVID-19: a randomized controlled trial

Character

Sodium chloride

TSPP

p (Fisher exact probability test)

Sample size, n

32

32

Age (years), mean ± SD

37.98 ± 6.27

36.87 ± 5.25

Days since symptoms to enrollment, mean ± SD

96.54 ± 4.12

94.81 ± 3.89

Gender

 Male, n

14

12

0.79

 Female, n

18

20

0.79

Smokers (current/never), n

5/32

4/32

1.00

Comorbidities, n

 Asthma

4

5

1.00

 Diabetes

2

4

0.67

 Hypertension

3

3

1.00

 Migraine

4

5

1.00

 Hyperuricemia

2

3

1.00

Current medication

 Anti-histamine

4

5

1.00

 Metformin

1

2

1.00

 Glimepiride

1

2

1.00

 ACE inhibitor

3

3

1.00

 Paracetamol

4

5

1.00